Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and Immunome (NASDAQ:IMNM – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.
Insider & Institutional Ownership
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and target prices for Arbutus Biopharma and Immunome, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arbutus Biopharma | 0 | 1 | 1 | 0 | 2.50 |
| Immunome | 1 | 1 | 12 | 0 | 2.79 |
Profitability
This table compares Arbutus Biopharma and Immunome’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arbutus Biopharma | 84.22% | 90.98% | 82.34% |
| Immunome | N/A | -50.56% | -46.93% |
Risk and Volatility
Arbutus Biopharma has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Immunome has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500.
Valuation & Earnings
This table compares Arbutus Biopharma and Immunome”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arbutus Biopharma | $14.08 million | 65.71 | -$33.50 million | $0.79 | 5.91 |
| Immunome | $6.94 million | 346.47 | -$212.39 million | ($2.53) | -8.37 |
Arbutus Biopharma has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Arbutus Biopharma beats Immunome on 8 of the 14 factors compared between the two stocks.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
